泮托拉唑与替普瑞酮治疗慢性糜烂性胃炎临床疗效观察  

Observation on the Clinical Effect of Pantoprazole and Teprenone in the Treatment of Chronic Erosive Gastritis

作　　者：李仲明[1] 黄志明[1] LI Zhong-ming;HUANG Zhi-ming(Wuchuan People's Hospital,Guangdong Wuchuan 524500)

机构地区：[1]吴川市人民医院,广东吴川524500

出　　处：《深圳中西医结合杂志》2021年第22期193-194,共2页Shenzhen Journal of Integrated Traditional Chinese and Western Medicine

摘　　要：目的:探讨泮托拉唑与替普瑞酮治疗效果和用药安全性。方法:选取2018年5月至2019年10月在吴川市人民医院进行治疗的100例慢性糜烂性胃炎患者,按照入院顺序分为对照组和观察组,各50例。观察组进行泮托拉唑与替普瑞酮治疗,对照组进行泮托拉唑治疗,将各组指标进行比较。结果:观察组患者治疗后丙二醛(MDA)水平低于对照组,前列腺素F2α(PGF2α)水平高于对照组,差异具有统计学意义(P<0.05)。观察组患者不良反应发生率低于对照组,差异具有统计学意义(P<0.05)。观察组治疗总有效率高于对照组,差异具有统计学意义(P<0.05)。结论:通过对慢性糜烂性胃炎患者实施泮托拉唑与替普瑞酮治疗,具有一定的临床效果及较高的用药安全性。Objective To investigate the efficacy and safety of pantoprazole and tiprezone.Methods 100 patients with chronic erosive gastritis treated in Wuchuan People’s Hospital from May 2018 to October 2019 were divided into control group and observation group,with 50 cases in each group.The observation group was treated with pantoprazole and teprenone,and the control group was treated with pantoprazole.The indexes of each group were compared.Results After treatment,the level of malondialdehyde (MDA) in the observation group was lower than that in the control group,and the level of prolandin F2α (PGF2α) was higher than that in the control group (P < 0.05).The incidence of adverse reactions in the observation group was lower than that in the control group (P < 0.05).The total effective rate of the observation group was higher than that of the control group (P < 0.05).Conclusion By using pantoprazole and tiprezone in the treatment of chronic erosive gastritis,it has certain clinical effect and high drug safety.

关 键 词：慢性糜烂性胃炎 泮托拉唑 替普瑞酮 

分 类 号：R573.3[医药卫生—消化系统]